Sangamo Therapeutics (NASDAQ:SGMO) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report released on Saturday.
SGMO has been the topic of a number of other research reports. Zacks Investment Research lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. Piper Jaffray Companies raised Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price objective on the stock in a research report on Wednesday, November 15th. Wedbush reaffirmed a “neutral” rating and set a $6.00 price objective on shares of Sangamo Therapeutics in a research report on Monday, February 12th. Finally, Barclays started coverage on Sangamo Therapeutics in a research report on Wednesday, November 22nd. They set an “overweight” rating and a $20.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Sangamo Therapeutics has a consensus rating of “Buy” and an average price target of $18.83.
Sangamo Therapeutics (NASDAQ:SGMO) opened at $23.30 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64. Sangamo Therapeutics has a 52 week low of $3.65 and a 52 week high of $23.75. The company has a market capitalization of $1,970.00, a price-to-earnings ratio of -33.77 and a beta of 2.87.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The business had revenue of $11.81 million for the quarter, compared to analyst estimates of $10.37 million. During the same quarter in the prior year, the company earned ($0.27) earnings per share. The company’s revenue was up 333.0% on a year-over-year basis. sell-side analysts predict that Sangamo Therapeutics will post -0.73 EPS for the current fiscal year.
In related news, VP Curt A. Herberts III sold 16,630 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $16.13, for a total value of $268,241.90. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Curt A. Herberts III sold 15,000 shares of the stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $17.26, for a total value of $258,900.00. Following the completion of the transaction, the vice president now directly owns 13,015 shares in the company, valued at approximately $224,638.90. The disclosure for this sale can be found here. Insiders have sold 84,953 shares of company stock worth $1,544,843 in the last ninety days. Corporate insiders own 5.50% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. MetLife Investment Advisors LLC purchased a new position in Sangamo Therapeutics in the fourth quarter valued at $643,000. Macquarie Group Ltd. increased its holdings in Sangamo Therapeutics by 1,016.7% in the fourth quarter. Macquarie Group Ltd. now owns 20,100 shares of the biopharmaceutical company’s stock valued at $330,000 after buying an additional 18,300 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its holdings in Sangamo Therapeutics by 70.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 19,189 shares of the biopharmaceutical company’s stock valued at $314,000 after buying an additional 7,900 shares during the last quarter. Cornerstone Capital Management Holdings LLC. purchased a new position in Sangamo Therapeutics in the fourth quarter valued at $707,000. Finally, TIAA CREF Investment Management LLC increased its holdings in Sangamo Therapeutics by 23.0% in the fourth quarter. TIAA CREF Investment Management LLC now owns 883,382 shares of the biopharmaceutical company’s stock valued at $14,487,000 after buying an additional 164,900 shares during the last quarter. 64.22% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This story was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.thelincolnianonline.com/2018/02/19/sangamo-therapeutics-sgmo-upgraded-by-bidaskclub-to-strong-buy.html.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.